Is Inhibrx, Inc. overvalued or undervalued?

As of 12 October 2023, Inhibrx, Inc. moved from fair to attractive. The company is currently undervalued based on its financial metrics. Key ratios include a price-to-earnings (P/E) ratio of 15.2, a price-to-sales (P/S) ratio of 3.5, and a return on equity (ROE) of 10.1%.
When compared to its peers, such as Amgen with a P/E of 18.5 and Regeneron Pharmaceuticals at a P/E of 20.3, Inhibrx appears to be trading at a discount. This valuation is further supported by its recent stock performance, which has outpaced the Sensex, reinforcing the attractiveness of its current price point.